Clinical trial
A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease
NCT06881836 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, 26-week, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of ONO-2020 in Patients With Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 24, 2025
- Completion date
- September 1, 2026
- Enrollment
- 260 (actual)
- Sites
- 80
Conditions
As the registry lists them; a condition with its own page is linked.